Pulmonary venous occlusion and death in pulmonary arterial hypertension: survival analyses using radiographic surrogates by Takeda, Yasuko et al.
RESEARCH ARTICLE Open Access
Pulmonary venous occlusion and death in
pulmonary arterial hypertension: survival analyses
using radiographic surrogates
Yasuko Takeda
1,2, Yutaka Takeda
1*, Koji Yamamoto
1, Shigehiro Tomimoto
1, Tomomitsu Tani
1, Hitomi Narita
2,
Nobuyuki Ohte
1 and Genjiro Kimura
1
Abstract
Background: Recent studies find that a considerable number of patients with pulmonary arterial hypertension
(PAH) develop fibrous obstruction of the pulmonary veins. Such obstruction more commonly accompanies
connective tissue disorder (CTD)-associated PAH than idiopathic PAH. However, few researchers have gauged the
risk of death involving obstruction of the pulmonary veins.
Methods: Thirty-seven patients with PAH were enrolled (18 patients, idiopathic PAH; 19 patients, CTD-associated
PAH). The patients were 49 ± 18 years and had a World Health Organization functional class of 3.2 ± 0.6.
Thickening of the interlobular septa, centrilobular ground-glass attenuation, and mediastinal adenopathy were
surrogates for obstruction of the pulmonary veins, and were detected by a 16-row multidetector computed
tomography scanner.
Results: The follow-up period was 714 ± 552 days. Fifteen deaths occurred. Thickening of the interlobular septa,
centrilobular ground-glass attenuation, and mediastinal adenopathy were found in 37.8%, 24.3%, and 16.2% of
patients, respectively. Cox proportional hazard analysis revealed an increased risk of death with each radiographic
surrogate (mediastinal adenopathy: p < 0.0001, hazard ratio = 13.9; thickening of interlobular septa: p < 0.001,
hazard ratio = 12.0; ground-glass attenuation: p = 0.02, hazard ratio = 3.7). The statistical significance of these
relationships was independent of the cause of PAH and plasma concentration of brain natriuretic peptide.
Conclusions: The results of this study imply that obstruction of the pulmonary veins is associated with an
increased risk of death in patients with PAH.
Background
Pulmonary arterial hypertension (PAH) carries a signifi-
cant risk of death [1,2]. Patients with a poor response to
pulmonary vasodilating agents often die within several
years [1]. Recent studies show that a considerable num-
ber of patients with PAH develop fibrous obstruction in
the pulmonary veins [3,4]. These findings challenge rela-
tionship between clinical entity of PAH and that of pul-
monary veno-occlusive disease (PVOD). Case reports
suggest that obstruction of pulmonary veins is asso-
ciated with a poor prognosis [5-8]. However, few
researchers have gauged the risk of death due to pul-
monary venous obstruction. To assess the effect of pul-
monary venous obstruction on the risk of death in
patients with PAH, this study performed survival ana-
lyses with patients grouped by the cause of PAH and by
the presence or absence of radiographic surrogates for
obstruction of the pulmonary veins.
Methods
The patients
Forty-five patients with idiopathic PAH or connective
tissue disorder (CTD)-associated PAH were referred to
our PAH clinic from January 2004 to March 2009. We
excluded eight patients from analyses for the following
reasons: a total lung capacity less than 70% of the
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centration greater than 2.5 mg/dL (two patients); an age
greater than 75 years (two patients); the presence of
liver cirrhosis (one patient); and the presence of gastric
cancer (one patient). The remaining 37 study partici-
pants (8 men and 29 women) gave informed consent.
PAH was diagnosed from the results of right heart
catheterisation at rest [9,10]. PAH was defined as a
mean pulmonary artery pressure greater than 25 mm
Hg, a pulmonary capillary wedge pressure less than or
equal to 15 mm Hg, and pulmonary vascular resistance
greater than 3 Wood units. All of the patients com-
pleted the evaluations, as described below. However, the
data of right heart catheterisation from 11 patients were
not used for analyses for the change of the treatment
between catheterisation and the other baseline evalua-
tions. Pulmonary arterial thromboembolism was not
detected in any of the patients with a lung perfusion
scan. The institutional ethics committee approved the
protocol. All the participants gave informed consent to
this study.
Assessment of radiographic surrogates of pulmonary
venous obstruction
Thickening of the interlobular septa, the presence of
centrilobular ground-glass attenuation, and enlargement
of the mediastinal lymph nodes were surrogates for
obstruction of the pulmonary veins; these surrogates
were detected with computed tomography (CT) scans
(Figure 1) [5,7-9,11-16]. The details of these abnormal-
ities are described elsewhere [15,17-19]. A 16-row multi-
detector CT scanner (IDT 16, Philips Electronic Japan
Medical Systems, Tokyo, Japan) used the following scan
parameters: simultaneous acquisition of 16 slices per
rotation with a slice thickness of 0.75 mm, rotation time
of 500 ms, pitch of 0.9 mm, tube voltage of 120 kV, and
tube current of 200 mA. Cross-sectional images were
reconstructed with a slice thickness of 3.0 mm at 3.0-
mm intervals. Board-certified radiologists gave reports
on the CT images within 24 hours after the scans. Our
radiologists were not restricted from other clinical data.
Two investigators assessed the CT images and the
reports for the surrogates within a few days thereafter.
Final decisions were reached by consensus if there was
an inconsistency.
Assessment of the pulmonary hypertension status
One investigator assessed each patient’sf u n c t i o n a lc l a s s
in accordance with the World Health Organisation
(WHO) criteria. The patients underwent an overnight
fast. Blood samples were afterwards drawn from a per-
ipheral vein. The samples were immediately placed on
ice and centrifuged at 4°C. The plasma concentration of
brain natriuretic peptide (BNP) was then measured. An
external laboratory (SRL Inc., Tokyo, Japan) measured
BNP concentrations using an immunoradiometric assay.
A trained sonographer recorded all echocardiograms
using a commercially available system (SSA-770A,
Toshiba Medical Co. Ltd, Tokyo, Japan). The cardiac
index and Doppler right ventricular index were calcu-
lated using Doppler echo techniques [20]. Each mea-
surement was the average of three or more consecutive
beats at the end expiration.
Follow-up
The baseline was defined as the day of the CT scan. CT
scan was taken just before initiation of treatment in out
institute. The patients were asked to visit our outpatient
clinic every four weeks to adjust medical therapy and to
obtain information on clinical events. In addition to
these periodical contacts, the investigators and the
patients sometimes communicated by phone. (If a
patient did not come, the investigators interviewed the
patients or their family by phone.) The treatment was
not controlled because of the generally high mortality.
Treatment failure was defined as death, hospitalisation
due to cardiovascular events (including syncope), use of
inotropic agents, elevation of a patient’sW H Of u n c -
tional class, or a three-fold increase in the plasma BNP
concentration [21].
Statistical analyses
Statistical analyses were performed with the Statistical
Package for Social Science version 15.0 for Windows
(SPSS Inc., Chicago, Illinois). Survival times were
defined as the length of time a patient lived from the
baseline date to Dec 31, 2009. Data are expressed as the
Figure 1 The computed tomography scan of a 25-year-old
woman with severe idiopathic pulmonary arterial hypertension
reveals thickening of the interlobular septa (arrowheads) and
small multifocal areas of centrilobular ground-glass
attenuation.
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Page 2 of 8mean ± the standard deviation. The plasma BNP con-
centrations were transformed to their natural logarithms
to normalise the distribution, and the BNP data are
expressed as the median with the 25th and 75th percen-
tiles. Categorical variables were compared using the chi-
square test. The effect of each radiographic surrogate
for pulmonary venous obstruction and the effect of each
cause of PAH in relation to the patients’ characteristics
were tested with a two-way analysis of variance. The
prognostic values of the variables were tested using Cox
proportional-hazards regression analyses. The results are
expressed as the hazard ratios with 95% confidence
intervals. The Kaplan-Meier method produced the survi-
val curves. A two-sided p value less than 0.05 was con-
sidered statistically significant.
Results
Patients’ characteristics and follow-up results
Table 1 shows the characteristics of the patients. The
follow-up period was 714 ± 552 days. All patients main-
tained their follow-up visits. Death occurred in 5 (24%)
class III patients and in 10 (83%) class IV patients, but
no deaths occurred in class II patients (p <0 . 0 0 1 ) .
Death occurred in 9 (50%) in patients with idiopathic
PAH and in 6 (32%) in patients with CTD-associated
PAH (p = 0.23). Heart failure was the cause of death in
all but two mortality cases. One of these two patients
died of septic shock and the other died of a massive
lung haemorrhage. Treatment failure occurred in 10
(83%) class IV patients; nine (43%) class III patients; and
one (20%) class II patient (p = 0.038). No patient
received lung or heart-lung transplantation. All patients
experienced an increase in the use of pulmonary vasodi-
lating agents.
Radiographic surrogates for obstruction of the pulmonary
veins
The frequency of each radiographic surrogate for pul-
monary venous obstruction was shown in Table 2.
There was no statistical difference between the causes of
PAH in the frequency of each surrogate (mediastinal
adenopathy: p = 0.21; thickening of interlobular septa: p
= 0.42; ground-glass attenuation: p = 0.77). The haemo-
dynamic data and plasma concentration of BNP were
comparable between the causes of PAH. Mediastinal
adenopathy was associated with an advanced age and a
high plasma concentration of BNP. Thickening of inter-
lobular septa was associated with a low cardiac index
and high plasma concentration of BNP. Centrilobular
ground-glass attenuation was not associated with any of
the haemodynamic data or with the plasma concentra-
tion of BNP.
Radiographic surrogates tended to appear with each
other. Four patients had three surrogates; nine patients
had two surrogates; two patients had one surrogate, and
22 patients had no surrogates.
Survival rate and radiographic surrogates for obstruction
of the pulmonary veins
Survival analyses showed that each radiographic surro-
gate for pulmonary venous obstruction was associated
with a seriously increased risk of death. Cox propor-
tional hazard analysis using mediastinal adenopathy as
a surrogate found that the adenopathy was associated
with a seriously increased risk of death (p < 0.0001;
hazard ratio [95%CI]) = 13.9 [4.2 - 47.6]). Adding the
cause of PAH to the covariate did not weaken the rela-
tionship between mediastinal adenopathy and the risk
of death (adenopathy: p < 0.00001, hazard ratio [95%
CI]) = 14.1 [4.1 - 47.9]; causes of PAH: p =0 . 2 6 ) ;t h e
survival curves of patients with each cause of PAH
were close after being stratified by the presence or
absence of mediastinal adenopathy (Figure 2). Given
the relationship with an elevated plasma concentration
of BNP, Cox proportional analysis was also performed
by adding the plasma BNP concentration to the covari-
ates. The analysis showed that the adenopathy was
associated with a seriously increased mortality rate
independently of the BNP concentration (adenopathy:
p = 0.006, hazard ratio [95%CI] = 7.0 [1.9 - 26.3];
BNP: p = 0.013, hazard ratio [95%CI] = 2.0 [1.2 - 3.4];
the causes of PAH: p = 0.78).
Table 1 Baseline characteristics of the patients
Variables n = 37
Age (yrs) 49.0 ± 18.1
Women 29 (78.4)
Time from the onset to study enrolment (weeks) 14.2 ± 18.3
Functional class II/III/IV 4/21/12 (10.8/56.8/
32.4)
Idiopathic PAH/connective tissue disorder-
associated PAH
18/19 (48.6/51.4)
Death 15 (40.5)
Treatment failure* 20 (54.1)
Use of PAH-specific drug at baseline
Epoprostenol alone 11 (29.7)
Sildenafil alone 4 (10.8)
Bosentan alone 6 (16.2)
Beraprost alone 13 (35.1)
Epoprostenol + Sildenafil 1 (2.7)
Sildenafil + Beraprost 1 (2.7)
Sildenafil + Bosentan + Beraprost 1 (2.7)
Oxygen 33 (89.2)
Values are presented as the number (percent) or as the mean ± standard
deviation (SD).
*Treatment failure was defined as death, hospitalisation due to cardiovascular
event (including syncope), use of inotropic agents, or elevation in a patient’s
WHO functional class.
Abbreviation: PAH, pulmonary arterial hypertension.
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Page 3 of 8Table 2 Characteristics of the patients with each sign of pulmonary venous obstruction
Signs Cause n Age(years) mRAP(mm Hg)
§ mPAP (mm Hg)
§ CI(L/min/m2) BNP(pg/mL)
Mediastinal Yes Idiopathic 6 56 ± 18*,
# 9 ± 4 43 ± 5 1.9 ± 0.4 860 [637 - 1210]**
adenopathy CTD 3 65 ± 3*,
# 8 ± 3 36 ± 19 2.5 ± 0.3 148 [83 - 959]**
No Idiopathic 12 37 ± 17*,
# 8 ± 3 62 ± 16 2.4 ± 0.7 133 [37 - 418]**
CTD 16 52 ± 16*,
# 7 ± 4 48 ± 19 2.5 ± 0.9 141 [75 - 334]**
Thickening of Yes Idiopathic 8 50 ± 19 9 ± 5 56 ± 16 1.9 ± 0.4* 800 [487-1062]*
interlobular septa CTD 6 49 ± 18 7 ± 4 42 ± 18 2.0 ± 0.4* 482 [83-959]*
No Idiopathic 10 38 ± 19 7 ± 2 56 ± 16 2.5 ± 0.7* 92 [28 - 333] *
CTD 13 56 ± 14 7 ± 3 42 ± 18 2.7 ± 0.9* 126 [34 - 290]*
Centrilobular Yes Idiopathic 4 39 ± 20 9 ± 5 56 ± 16 2.1 ± 0.5 487 [236 - 715]
ground-glass CTD 5 54 ± 24 9 ± 4 49 ± 15 2.0 ± 0.5 148 [141 - 959]
attenuation No Idiopathic 14 45 ± 19 8 ± 3 61 ± 18 2.3 ± 0.7 263 [46 - 806]
CTD 14 55 ± 13 6 ± 3 45 ± 20 2.7 ± 0.9 111 [34 - 334]
Values are number (percent) or mean ± SD, as appropriate. Data of BNP are shown as median [25percentile, 75percentile]. P values for the comparison between
the patients with and without each radiographic surrogate for obstruction of the pulmonary veins; *: < 0.02 and **: < 0.01. P values for the comparison for the
difference between the causes;
# : < 0.03. No mark means that there is no significant effect of either the presence and absence of each radiographic surrogate or
the difference in the cause.
§: The values for mRAP and mPAP are based on 26 patients. BNP = brain natriuretic peptide, CI = cardiac index, CTD = connective
tissue disorder, mRAP = mean right atrial pressure, mPAP = mean pulmonary arterial pressure, RV = right ventricle, SD = standard deviation.
Days
Survival rate Idiopathic PAH without adenopathy
CTD-associated PAH without adenopathy
CTD-associated PAH with adenopathy
Idiopathic PAH with adenopathy
Comparison between patients with and without mediastinal adenopathy
p < 0.00001, hazard ratio (95%CI) = 14.1 (4.1 – 47.9)
Comparison between the different causes of PAH
p = 0.26
Figure 2 Kaplan-Meier survival curves of the patients showing the comparison between the presence or lack of mediastinal
adenopathy and between idiopathic and connective-tissue-disorder-associated pulmonary arterial hypertension.
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ing of the interlobular septa was also associated with a
seriously increased risk of death (p <0 . 0 0 1 ;h a z a r dr a t i o
[95%CI] = 12.0 [3.2 - 45.5]). Adding the cause of PAH
to the covariate had little impact on the relationship
between this surrogate and the risk of death (thickening:
p < 0.001, hazard ratio [95%CI] = 11.6 [3.1 - 43.5]; the
causes of PAH: p = 0.29); the survival curves of patients
with each cause of PAH were, similar to the results of
mediastinal adenopathy, close after stratification by the
presence or absence of thickening of the interlobular
septa (Figure 3). Given the relationship with an elevated
plasma BNP concentration, Cox proportional analysis
was also performed by adding the plasma BNP concen-
tration to the covariates. The analysis again showed that
interlobular septal thickening was associated with a ser-
iously increased mortality rate independently of the con-
centration of BNP (thickening: p = 0.004, hazard ratio
[95%CI] = 8.9 [1.9 - 41.7]; BNP: p = 0.005, hazard ratio
[95%CI] = 2.0 [1.3 - 3.3]; the causes of PAH: p = 0.30).
The presence of centrilobular ground-glass attenuation
was also associated with an increased risk of death,
although the effect with this surrogate was somewhat
milder than with the other surrogates (p = 0.02, hazard
ratio [95%CI] = 3.7 [1.2 - 11.1]). Adding the causes of
PAH to the covariate had little impact on the relation-
ship between this surrogate and the risk of death
(attenuation: p = 0.02, hazard ratio [95%CI] = 3.6 [1.2 -
10.8]; the causes of PAH: p = 0.24); the survival curves
were somewhat close in patients with ground glass
attenuation regardless the cause of PAH, although this
is less clear than with the other two surrogates (Figure
4). Despite the relationship between this surrogate and
the elevation of plasma BNP level did not reach the sta-
tistical significance, Cox proportional analysis was per-
formed by adding plasma concentration of BNP to the
covariates. The analysis again showed that ground-glass
attenuation was associated with a seriously increased
mortality rate independently of the BNP concentration
(attenuation: p = 0.016, hazard ratio [95%CI] = 4.8 [1.3 -
Days
Survival rate Idiopathic PAH without thickening
CTD-associated PAH without thickening
CTD-associated PAH with thickening
Idiopathic PAH with thickening
Comparison between patients with and without thickening of the interlobular 
septa
p < 0.001, hazard ratio (95%CI) = 11.6 (3.1 – 43.5)
Comparison between the different causes of PAH
p = 0.29
Figure 3 Kaplan-Meier survival curves of the patients showing the comparison between the presence and lack of thickening of the
interlobular septa and between idiopathic and connective-tissue-disorder-associated pulmonary arterial hypertension.
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Page 5 of 816.9]; BNP: p < 0.001; hazard ratio [95%CI] = 2.7 [1.6 -
4.5]; the causes of PAH: p = 0.15).
Discussion
Few studies have assessed obstruction of the pulmonary
veins for the risk of death in patients with PAH. The
results of the current investigation imply that pulmonary
venous obstruction is associated with an elevated risk of
death in patients with either idiopathic PAH or CTD-
associated PAH. The risk is very large for both causes of
PAH. This implication is based on the results of Cox
proportional hazard analysis using each radiographic
surrogate of pulmonary venous obstruction as follows:
mediastinal adenopathy, hazard ratio for death = 13.9 (p
< 0.0001); thickening of the interlobular septa, hazard
ratio = 12.0 (p < 0.001); and ground-glass attenuation,
hazard ratio = 2.0 (p = 0.02).
Recent studies found that obstruction of the pulmon-
ary veins develops in considerable proportion of patients
with idiopathic or CTD-associated PAH [3,4]. Dorfmül-
ler et al. report that 75% of patients with CTD-
associated and 17% of patients with non-CTD-associated
PAH showed obstruction of the pulmonary veins [3].
Overbeek et al. reported that pulmonary venous
obstruction was present in 87.5% of patients with sclero-
derma-associated PAH and in 37.5% of patients with
idiopathic PAH [4]. Thus, the differentiation of clinical
entities between PAH and PVOD is currently
challenged.
For several reasons, obstruction of the pulmonary veins
is believed to be related to a malignant prognosis. First,
most case reports show that patients with pulmonary
venous obstruction die within two years of diagnosis
[5-8]; this seems much worse than typical patients with
PAH [1,2]. Second, Resten et al. suggest that radiographic
surrogates of pulmonary venous obstruction are asso-
ciated with a poor prognosis [17]. The last report is very
important; however, the authors’ conclusions were wea-
kened by the study’s retrospective design and a lack of
survival time analyses [17]. Other than this report, few
reports exist examining the effect of pulmonary venous
obstruction on the survival of patients with PAH.
Days
Survival rate Idiopathic PAH without attenuation
CTD-associated PAH without attenuation
CTD-associated PAH with attenuation
Idiopathic PAH with attenuation
Comparison between patients with and without ground-glass attenuation
p = 0.021, hazard ratio (95%CI) = 3.6 (1.2 – 10.8)
Comparison between the different causes of PAH
p = 0.24
Figure 4 Kaplan-Meier survival curves of the patients showing the comparison between the presence and lack of ground-glass
attenuation and between idiopathic and connective-tissue-disorder-associated pulmonary arterial hypertension.
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pulmonary venous obstruction had a serious impact on
the survival of the patients (Figures 2, 3, and 4). In addi-
tion, the surrogates were associated with an increased
risk of death independently of the baseline BNP plasma
concentration. Therefore, the effect of pulmonary
venous obstruction on the mortality rate seemed inde-
pendent of a poor baseline condition. The survival rate
of patients with each surrogate is similar to the reported
survival rate of patients with proven pulmonary venous
obstruction (as assessed by pathological examinations)
[5-8]. Thus, the results of the current study suggest
great significance of pulmonary venous obstruction as a
mortality determinant.
Studies find that the mortality rate of CTD-associated
PAH is either double or triple that of idiopathic PAH
[22-25]. The reason for this discrepancy, however, is
unclear. The results of the current study may provide a
suggestion of possible cause of this discordance. As
described above, one-half or more of patients with
CTD-associated PAH have pulmonary venous obstruc-
tion, whilst only a minority of patients with idiopathic
PAH do [3,4]. In the present study, dividing the patients
by the presence or absence of each radiographic surro-
gate for pulmonary venous obstruction made the survi-
val curves of patients with each cause of PAH close
( F i g u r e2 ,3 ,a n d4 ) .T h e s ef i ndings suggest, therefore,
that the reason for the generally worse prognosis of
CTD-associated PAH, compared with idiopathic PAH, is
explained by the difference in the frequency of pulmon-
ary venous obstruction at least in part. Given a lack of
statistical significance in the difference of mortality rate
between the causes of PAH in this particular patients
group, further studies are needed to test this possible
explanation for the discordance in prognosis.
Radiographic signs can be used as surrogates as in this
study [15]. Studies find that pulmonary radiographic
signs on high-resolution CT scan images are successful
surrogates for obstruction of the pulmonary veins [15].
A direct diagnosis of pulmonary venous obstruction
requires a lung biopsy [11,12]. However, this procedure
is hazardous and is available only for select patients
[11,12]. In addition, guidelines discourage performing a
biopsy in frail PAH patients [11,12]. Thickening of the
interlobular septa, mediastinal adenopathy, and ground-
glass attenuation are characteristic signs on CT images
for obstruction of the pulmonary veins [11,12,15]. A
previous study demonstrates that the sensitivity and spe-
cificity for pulmonary venous obstruction of each radio-
graphic surrogate are as follows: mediastinal
adenopathy, 80% and 100%, respectively; thickening of
the interstitial septa, 93%, and 87%, respectively; and the
presence of ground-glass attenuation, 87%, and 67%,
respectively [15]. Results of two other studies using CT
scans agree with these findings [8,26]. The results of
pathological studies additionally support the rationale
for using radiographic surrogates. Pathological studies
demonstrate that interstitial pulmonary edema is
observed in a few patients without and most patients
with obstruction of the pulmonary veins
[3-5,7,8,13,14,26]. Mediastinal adenopathy is moreover
recognised as a frequent and very suggestive radiological
feature of pulmonary venous obstruction [8,15,16,26].
From these findings, it is apparently possible to use
radiographic signs as surrogates for obstruction of the
pulmonary veins as in this study. In consideration of the
procedural risks, the current study refrained from per-
forming invasive lung biopsies; however, we believe the
conclusions of this study are acceptable.
This study had several limitations. This is a single
centre investigation; this study therefore has referral
biases. We accepted only select patients - the majority
of whom had experienced treatment failure at their
referring hospitals. This bias was reflected by the poor
prognosis of the study patients, the relatively frequent
pulmonary venous obstruction among the patients
with idiopathic PAH, and a lack of statistical signifi-
cance in the difference in mortality rate between the
patients with idiopathic PAH and those with CTD-
associated PAH. Because of the limited number of the
patients, the predictive values of each radiographic sur-
rogate were not compared with other characteristics
but plasma concentration of BNP. The statistical ana-
lyses may have been weak due to the small samples
size. Despite of the excellent accuracy, the radiographic
surrogates might not completely detect pulmonary
venous obstruction.
Conclusions
In conclusion, the results of this study imply that
obstruction of the pulmonary veins is associated with a
seriously increased risk of death in patients with PAH.
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